GE ends Immelt era with another earnings beat, stock pullback >>> READ MORE

5 Biotech Stocks That Are Buyout Candidates

Current drug portfolios and pipelines make these biopharma names near-term acquisition targets

      View All  

Acorda Therapeutics (ACOR)

biotech-stocks-ACOR-stockThough the disease has been studied since 1868, it has only been in the past few years that medical science has understood multiple sclerosis well enough to develop meaningful treatments for it. Indeed, it’s only been very recently that big pharma has felt the field is promising enough to bother with, and very few biotech stocks have significantly benefited from these R&D advances.

Enter Acorda Therapeutics (ACOR). Acorda Therapeutics has three drugs on the market, but the big Kahuna is Ampyra, for multiple sclerosis patients who have difficulty walking. Last year, the company sold $302.6 million worth of Ampyra. It’s not a lot, but it’s a lot for a company that doesn’t have much marketing clout. In the hands of a company with more sales firepower wanting to get into the $11 billion MS market, however, Ampyra makes ACOR one of the few biotech stocks in the arena worth a suitor’s consideration.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC